Incomplete lupus in adults. who, when, and how to treat?

Systemic lupus erythematosus (SLE) often evolves from a preclinical phase, characterized by immune dysregulation and incomplete clinical manifestations that do not meet classification criteria. This article explores the spectrum of incomplete lupus erythematosus (ILE) and its potential transition to classified SLE. Notably, a significant proportion of ILE patients exhibit various clinical manifestations, including autoimmune abnormalities and organ damage, despite not fulfilling formal SLE criteria. Recent studies suggest that 10–50% of ILE cases may progress to SLE within five years, often presenting a milder form without severe organ involvement. The article highlights the need for improved screening and monitoring strategies for people with a high risk of SLE, particularly those with risk factors or serological abnormalities. Current guidelines lack comprehensive management approaches for ILE patients either symptomatic or asymptomatic, emphasizing the necessity for further research into preventive therapies, such as hydroxychloroquine, to mitigate disease progression. Ultimately, understanding the pathogenesis and clinical management of incomplete forms of SLE is crucial for early intervention and improved patient outcomes.